Analysts See $0.21 EPS for Swedish Orphan Biovitrum AB (publ)

June 13, 2018 - By Judy Temple

Swedish Orphan Biovitrum AB (OTCMKTS:publ) Logo

Analysts expect Swedish Orphan Biovitrum AB (OTCMKTS:publ) to report $0.21 EPS on July, 18.SWTUY’s profit would be $55.27 million giving it 25.48 P/E if the $0.21 EPS is correct. After having $0.24 EPS previously, Swedish Orphan Biovitrum AB’s analysts see -12.50 % EPS growth. It closed at $21.4 lastly. It is down 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, makes, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. The company has market cap of $5.63 billion. The Company’s core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease. It has a 42.29 P/E ratio. The firm also offers Elocta and Alprolix for the treatment of haemophilia; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.